EUVIMEDEUVIMED entdecken
Open Access

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

Jingchuan Guo iD, Huilin Tang iD, Hui Shao iD, Ying Lu, Lizheng Shi iD, Vivian A Fonseca iD, Hwayoung Cho, Yi Guo, Jiang Bian

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Jingchuan Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Parkinson Disease, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Diabetes increases the risk of Parkinson disease (PD). Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, a new glucose‐lowering therapeutic class, have shown neuroprotective effects in mechanistic studies. However, the association between SGLT2 inhibitors and PD risk in real‐world populations with type 2 diabetes (T2D) remains unclear.

Objective

The aim was to assess the association between SGLT2 inhibitors and the risk of PD in older populations with T2D. Design, Setting and Participants This retrospective cohort analysis used Medicare claims data from 2016 to 2020 to identify fee‐for‐service beneficiaries ≥65 years diagnosed with T2D and without pre‐existing PD. Exposures The initiation of an SGLT2 inhibitor was compared with that of a dipeptidyl peptidase‐4 (DPP4) inhibitor. Main Outcomes and Measures The outcome was the first incident PD ever since the date initiating either an SGLT2 inhibitor or a DPP4 inhibitor. We employed a 1:1 propensity score matching to balance the baseline covariates between treatment groups, including sociodemographics, comorbidities and co‐medications. We applied Cox regression models to assess the effect of SGLT2 inhibitors versus DPP4 inhibitors on incident PD.

Results

Of 89 330 eligible Medicare beneficiaries (mean age: 75 ± 7 years, 52% women), 0.6% ( n = 537) had incident PD over the follow‐up. After 1:1 propensity matching, the PD incidence was 2.5 and 3.5 events per 1000 person‐years in the SGLT2 inhibitor group and DPP4 inhibitor group, respectively. The SGLT2 inhibitor group was associated with a significantly lower risk of incident PD than the DPP4 inhibitor group (hazard ratio: 0.70 [95% confidence interval: 0.55–0.89]). There is a potential trend that the risk reduction in incident PD was profound in non‐Hispanic Black individuals and insulin users. Conclusion and Relevance Compared to DPP4 inhibitors, SGLT2 inhibitors were associated with a significantly lower risk of incident PD in older populations with T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Parkinson DiseaseDipeptidyl-Peptidase IV InhibitorsMedicareHumansFemaleMaleAgedRetrospective StudiesUnited StatesAged, 80 and overRisk FactorsIncidence

Stichwörter der Autor:innen

Parkinson diseasesodium‐glucose cotransporter 2 inhibitorstype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • Department of Global Health, Emory University Rollins School of Public Health, Atlanta, Georgia, USA.
  • Department of Health Policy and Management, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
  • Section of Endocrinology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • Department of Family, Community and Health Systems Science, University of Florida College of Nursing, Gainesville, Florida, USA.
  • Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.

ORCID-Profile: Jingchuan Guo, Huilin Tang, Hui Shao, Lizheng Shi, Vivian A Fonseca

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Guo, J., Tang, H., Shao, H., Lu, Y., Shi, L., Fonseca, V. A., Cho, H., Guo, Y., & Bian, J. (2024). Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15943

Vancouver

Guo J, Tang H, Shao H, Lu Y, Shi L, Fonseca VA, et al. Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15943

BibTeX
@article{Guo2024,
  author = {Guo, Jingchuan and Tang, Huilin and Shao, Hui and Lu, Ying and Shi, Lizheng and Fonseca, Vivian A and Cho, Hwayoung and Guo, Yi and Bian, Jiang},
  title = {Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15943}
}
Kostenlos starten →